Skip to main content

Table 2 Demographic data, the patient characteristics and ECMO data of 8 multicentre studies with H1N1 outbreak (2009–2010)

From: ECMO use in COVID-19: lessons from past respiratory virus outbreaks—a narrative review

Study groupData collection/populationECMO pts./total H1N1 pts.Age of ECMO pts. (years)PaO2/FIO2a (mmHg)MV durationa (days)ECMO duration (days)Discharged aliveb, n (%)
ANZ ECMO Influenza Investigator [40]Retrospective/15 ICUs68/19434.4 (26.6–43.1)56 (48–63)NA10 (7–15)32 (47.1%)
UK ERP with SwiFT study [41]Prospective/4 centres75c36.5 ± 11.454.9 ± 14.34.4 ± 3.7NA57 (76%)
Italian ECMO network [42]Prospective/14 ICUs60/15339 (32–46)63.3 (56–79)2 (1–5)10 (7–17)41 (68.3%)
Australian ERP [43]Retrospective38NA63NANA33 (86.8%)
Japanese Society [44]Retrospective/12 ICUs145450 (40–55)5 (0.8–8.5)8.5 (4.0–10.8)5 (35.73%)
REVA Research Network in France [45]Prospective/114 ICUs12342 ± 1363 ± 212 (1–5)9.879 (64.2%)
Germany ARDS network [46]Retrospective/40 centres61/11642 (39–45)d87 (74–101)dNANA28 (45.9%)
Italian ECMO network [47]Prospective/14 centres6039.7 ± 12NANANA41 (68.3%)
  1. Mean ± SD or median (interquartile range)
  2. ANZ Australia and New-Zealand, ECMO extracorporeal membrane oxygenation, ERP ECMO Retrieval Program, ICU intensive care unit, MV mechanical ventilation, NA not applicable, pts. patients, SwiFT Swine Flu Triage
  3. aData before ECMO support
  4. bDischarged alive of patients who underwent ECMO support
  5. cMatched pairs among total 80 ECMO referred patients
  6. dMean values (95% confidence interval)